A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

The trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.

When combined with a GLP-1 receptor agonist, the Activin E antibody produced additive effects, reducing total fat mass by 77%. Subcutaneous fat loss increased to 74%, while visceral fat depots ...

Arrowhead Pharmaceuticals has submitted an application to the New Zealand Medicines and Medical Devices Safety Authority seeking clearance to commence a Phase I/IIa trial of its investigational ...

Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. To date, it is the only approved medicine for both newly diagnosed and previously treated myelofibrosis ...

By reducing the activity of Activin E and its receptors, researchers believe it may be possible to develop therapeutics that could decrease internal abdominal fat, while preserving muscle mass to ...

Momelotinib is designed to inhibit 3 signaling pathways including Janus kinase (JAK) 1, JAK2, and activin A receptor type 1 (ACVR1). Inhibition of JAK1 and JAK2 is expected to improve ...

Next, Dr Vannucchi describes the final analysis from a phase 3 study evaluating jaktinib, a novel JAK and activin A receptor type 1 (ACVR1) inhibitor, compared with hydroxyurea in patients with MF.